29 completed, 3 recruiting, 3 terminated, 3 unknown. 43 Phase 2, 4 Phase 3, 2 Phase 1.
Follow Somatosensory Disorders: new trials by email Literature Review of Somatosensory Disorders trials Research Report on Somatosensory Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effectiveness of Oxitard Gel Versus Physiotherapeutic and Pharmacological Interventions in Alleviating Oral Submucous Fibrosis: A Phase-II Randomized Control Trial Herbal Formulation, Shekar's appliance, Multivitamin/Mineral supplements - Oral and Maxillofacial Conditions | Phase 2 | Not yet recruiting | Dow University of Health Sciences | 20 | 2026-11-15 | 2026-11-06 |
| Analgesic Efficacy and Safety of Topical VMD-3866 Gel in Management of Pain Induced by Chemotherapy (CIPN) VMD-3866 Gel, Placebo Gel - Chemotherapy-induced Peripheral Neuropathy, Chemotherapy-induced Neuropathic Pain | Phase 2 | Recruiting | VM Therapeutics LLC | 16 | 2025-12-12 | 2026-10-21 |
| Ozone Treatment in Paresthesia (Numbness, Tingling) Secondary to Chemotherapy-induced Peripheral Neuropathy Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-18 |
| Gut Microbiome Profiles in Patients With Chemotherapy-induced Neuropathy in the RCT OzoParQT (NCT06706544). Ozone therapy, Oxygen (placebo) - Chemotherapy Induced Peripheral Neuropathy (CIPN), Paresthesia | Phase 2 / Phase 3 | Recruiting | Bernardino Clavo, MD, PhD | 42 | 2025-02-07 | 2026-09-25 |
| Effect of Ultra-low Dose Naloxone on Remifentanil-Induced Hyperalgesia Remifentanil, Remifentanil+ Placebo, Remifentanil +ultra-low dose naloxone - Hyperalgesia | Phase 2 | Terminated | University of California, Irvine | 8 | 2023-02-25 | 2026-06-04 |
| Impact of Repeatedly-Administered THC-cannabis on Experimental Pain and Abuse Liability in Humans Active Cannabis, Placebo Cannabis - Cannabis, Pain | Phase 2 | Suspended | New York State Psychiatric Institute | 16 | 2021-08-01 | 2026-09-24 |
| Post-operative Analgesic Effect of Oral Nefopam Oral nefopam, Placebo - Postoperative Pain After a Total Knee Arthroplasty | Phase 2 | Active not recruiting | Hospices Civils de Lyon | 50 | 2021-06-29 | 2026-11-16 |
| Repeated Cannabis Administration on Experimental Pain and Abuse Liability Active Cannabis, Placebo Cannabis - Cannabis, Pain | Phase 2 | Completed | New York State Psychiatric Institute | 10 | 2021-06-01 | 2025-08-08 |
| Pilot Study to Compare Topical Voriconazole to Placebo as a Pain Reducing Agent Voriconazole (topical), Topical Sterile Water Placebo Group - Pain, Thermal Injury | Phase 2 | Withdrawn | Kenneth Hargreaves | 2018-06-15 | 2018-12-17 | |
| Can DFN-15 Terminate Migraine With Allodynia? DFN-15, Placebo - Migraine With Aura, Migraine Without Aura | Phase 2 | Completed | Hartford Hospital | 51 | 2018-05-09 | 2019-04-16 |
| Effect of High-dose Naloxone Following Third Molar Extraction Naloxone, Normal Saline - Healthy Subjects, Hyperalgesia | Phase 2 | Completed | mads u werner | 23 | 2017-10-12 | 2024-02-22 |
| Low-Dose Naltrexone and Acetaminophen Combination in the Treatment of Chronic Low Back Pain (ANODYNE-4) Low-dose naltrexone and acetaminophen combination, Placebo - Chronic Low Back Pain, Lumbar Radiculopathy | Phase 2 | Completed | Allodynic Therapeutics, Inc | 12 | 2017-08-15 | 2021-04-14 |
| Using Intranasal Midazolam (INM) and Lidocaine for Uncooperative Children Midazolam, Lidocaine-Midazolam, Placebo - Burning Nose | Phase 2 / Phase 3 | Completed | Latakia University | 63 | 2017-06-01 | 2018-11-05 |
| Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) DS-1971a, placebo, pregabalin - Neuropathic Pain, Diabetes | Phase 2 | Withdrawn | Daiichi Sankyo | 2016-02-01 | 2016-07-27 | |
| Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury Naloxone, Normal saline - Healthy Subjects | Phase 2 | Completed | mads u werner | 80 | 2016-02-01 | 2024-02-23 |
| Effect of High-dose Naloxone Infusion on Pain and Hyperalgesia in Patients Following Groin-Hernia Repair. Target-controlled naloxone-infusion, Placebo - Central Nervous System Sensitization, Pain | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 9 | 2015-11-11 | 2024-02-22 |
| ST266 in UV-induced Inflammation ST266 immediate, ST266 delayed - Skin Burns | Phase 2 | Completed | Noveome Biotherapeutics, formerly Stemnion | 10 | 2015-03-01 | 2019-05-15 |
| The Effect of Hyperbaric Oxygen Therapy on Inflammatory Parameters Induced by a Heat Injury Model Hyperbaric oxygen - Secondary Hyperalgesia, Inflammation | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 26 | 2015-02-01 | 2019-06-21 |
| Preoperative Intraarticular Injection of Methylprednisolone in Patients Scheduled for Total Knee-arthroplasty Methylprednisoloneacetate, Lidocaine, sodium chloride - Knee Joint Osteoarthrosis, Hyperalgesia | Phase 2 | Completed | Copenhagen University Hospital, Rigshospitalet | 48 | 2014-10-01 | 2016-06-06 |
| Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients Minocycline, Placebo, Questionnaires - Colorectal Cancer | Phase 2 | Completed | M.D. Anderson Cancer Center | 122 | 2013-11-01 | 2020-03-17 |
Showing 20 of 43. Sign in to see all of them.
Hyperalgesia (28) · Pain (18) · Paresthesia (10) · Hypesthesia (9) · Neuralgia (8) · Chronic Pain (5) · Agnosia (4) · Anxiety Disorders (3) · Marijuana Abuse (3) · Burns (2) · Depression (2) · Herpes Zoster (2) · Neuralgia, Postherpetic (2) · Pain, Postoperative (2) · Peripheral Nervous System Diseases (2)
Nervous System Diseases (43) · Neurologic Manifestations (43) · Pathological Conditions, Signs and Symptoms (43) · Sensation Disorders (43) · Signs and Symptoms (43) · Neuromuscular Diseases (9) · Pain (9) · Mental Disorders (7) · Peripheral Nervous System Diseases (7) · Wounds and Injuries (5) · Neurobehavioral Manifestations (4) · Pathologic Processes (4) · Perceptual Disorders (4) · Central Nervous System Diseases (3)
Saline Solution (4) · Dextromethorphan (2) · Lidocaine (2) · Naloxone (2) · Nefopam (2) · Oxygen (2) · Remifentanil (2) · rofecoxib (2) · AZD2066 (1) · Amantadine (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Bupivacaine (1) · Carvedilol (1) · Celecoxib (1)
Copenhagen University Hospital, Rigshospitalet (3) · National Institute of Dental and Craniofacial Research (NIDCR) (3) · Bernardino Clavo, MD, PhD (2) · Brigham and Women's Hospital (2) · New York State Psychiatric Institute (2) · Novalar Pharmaceuticals, Inc. (2) · mads u werner (2) · Aegera Therapeutics (1) · Allodynic Therapeutics, Inc (1) · AstraZeneca (1) · Azad University of Medical Sciences (1) · Cantonal Hospital of St. Gallen (1) · Center for Medicinal Cannabis Research (1) · Columbia Northwest Pharmaceuticals (1) · Daiichi Sankyo (1)
United States (25) · Denmark (5) · Canada (3) · France (2) · Spain (2) · Bulgaria (1) · Iran (1) · Pakistan (1) · Romania (1) · South Korea (1) · Switzerland (1) · Syria (1) · United Kingdom (1)
Bernardino Clavo, MD, PhD (2) · Bradley K Taylor, M.Sc., Ph.D. (2) · Christine N. Sang, MD, MPH (2) · Mads U Werner, MD, DMSc (2) · Annette Toledano, M.D. (1) · Ariana Nelson, MD (1) · Arifulla Khan, MD (1) · Bahman Jabbari, MD (1) · Biljana Lilja (1) · Brett Stacey (1) · Cathy Eng, MD, BA (1) · Christopher E White, MD (1)
PMID 16275600, PMID 21300053, PMID 23741350, PMID 24052307, PMID 26305798, PMID 11576045, PMID 15560360, PMID 16202520, PMID 22365565, PMID 23063945, PMID 23671631, PMID 24012952, PMID 25227929, PMID 26000320, PMID 26554360, PMID 27739142, PMID 30274305, PMID 30915992, PMID 41572235, PMID 8109774
R01NS041503 (2), R21DA050752 (1)